Lyxumia/Lantus combo cleared to start Phase III
This article was originally published in Scrip
Executive Summary
Zealand Pharma says it has received a $15m milestone from Sanofi related to the approval of a Phase III study protocol by an undisclosed health authority for LixiLan, a fixed-ratio combination of lixisenatide and Lantus (insulin glargine).